Pharsight Corporation Launches Phoenix NLME(TM), Continues to Build Next-Generation Platform for Model-Based Drug Development

ST. LOUIS--(BUSINESS WIRE)--Pharsight, a market-leading provider of software and scientific services to improve productivity and decision-making in clinical drug development, today announced the launch of Phoenix NLME (Nonlinear Mixed Effects), the next generation of the company’s data processing and modelling software for population pharmacokinetic and pharmacodynamic (PK/PD) analysis. Phoenix NLME 1.0 replaces Pharsight’s WinNonMix® and joins Phoenix™ WinNonlin® and Phoenix Connect™ on the Phoenix™ platform, Pharsight's new desktop software environment that is designed to advance model-based drug development by providing an integrated environment for data analysis, modeling and simulation.